Breaking News
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
June 15, 2018 - Fat and carb rich foods preferred by the brain
June 15, 2018 - Scientists discover unique feature in the ‘antennae’ of light-sensing neurons
June 15, 2018 - Researchers observe increase in activity of neurons grown on single layer of graphene
June 15, 2018 - Researchers find enzyme responsible for aircraft noise-related vascular damage
June 15, 2018 - Study shows improvements in adherence, outcomes of gout patients receiving text message reminders
June 15, 2018 - Accelerated brain maturation linked to stress in childhood
June 15, 2018 - FDA Alert: Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals
New Drugs on Horizon for Atopic Dermatitis

New Drugs on Horizon for Atopic Dermatitis

image_pdfDownload PDFimage_print

The evolution in the understanding of the pathogenesis of atopic dermatitis has fueled drug discovery in this arena.

Both T helper cell type 2 (TH2) lymphocyte-driven inflammation, and inflammatory mediators, have become specific targets for anti-inflammatory therapy, according to Lawrence Eichenfield, MD, a professor of dermatology and pediatrics at the University of California San Diego.

Eichenfield, co-author of a comprehensive article in Clinics in Dermatology on current and emerging topical agents for atopic dermatitis (AD), noted that for early intervention, several small studies have demonstrated that emollients decrease the rate of infants at risk for developing AD. Larger studies are underway, he said.

For established AD, rather than solely focusing on managing flares and treatment of acute disease, “we are starting to emphasize long-term disease control,” Eichenfield said. “Strategies to use topical agents in long-term models have a good evidence basis with either topical corticosteroids, which are generally used two to three times a week, or topical calcineurin inhibitors, which may be used intermittently.”

The goal of such a model is to create topical regimens that will minimize the signs and symptoms of disease, while delivering agents as safely as possible. “This mimics the model for control of asthma, which is not based on simply treating active wheezing, but incorporating a variety of medications to minimize the disease over long periods of time,” Eichenfield said.

In December 2016, crisaborole ointment 2% (Eucrisa) received FDA approval for the treatment of AD, making it “the first new novel agent since 2001,” according to Eichenfield. The phosphodiesterase (PDE)-4 inhibitor agent “is neither a topical corticosteroid nor a topical calcineurin inhibitor. It targets an inflammatory mediator and has been shown to work topically to decrease signs and symptoms of AD.”

Because crisaborole is not a corticosteroid, “there is no atrophy, telangiectasia, or hypopigmentation attributed to the drug’s use,” Eichenfield said.

Crisaborole was approved to treat mild to moderate eczema in pediatric (ages ≥2 years) and adult patients. It works by inhibiting phosphodiesterase 4 (PDE-4).

Eichenfield said he was pleased that crisaborole has been added to his armamentarium of AD therapy, either as monotherapy or along with other topical steroids. “We are using it most commonly in long-term care regimens to minimize patient exposure to topical corticosteroids,” he said.

Furthermore, the absence of limitation of duration of use “is highly valuable.” In his practice, crisaborole has been effective in controlling symptoms in his patients in which no significant adverse effects have been observed, he said.

There are currently other topical PDE-4 agents in development for AD along with agents that target janus kinase inhibitors. “The janus kinase pathway is one that apparently can be very important in mediating the inflammation of AD,” explained Eichenfield.

Currently, there are two approved oral janus inhibitors for non-dermatologic indications: Myelodysplasia and rheumatoid arthritis (RA). One of these inhibitors, tofacitinib (Xeljanz) for RA, “has also been studied for AD [but] that drug is not being actively developed at the present time,” Eichenfield said. “But there are many other janus inhibitors that are in clinical studies for AD.”

Eichenfield said the development of new topical therapies for AD is happening concurrently with the development and early use of both, along with other small molecular agents for systemic therapy.

“It is hoped that the heightened awareness about the disease will bring patients into the dermatologist to allow us to improve their AD and minimize the disease process,” Eichenfield said.

This article originally appeared on our partner’s website Dermatology Times, which is a part of UBM Medica. (Free registration is required.)

Eichenfield disclosed relevant relationships with Anacor (Pfizer), Medimetriks, and Roivant Sciences.

2017-12-09T14:00:00-0500

Tagged with:

About author

Related Articles